Tumor Susceptibility Gene 101 (TSG101) (Middle Region) Peptid
TSG101
Reaktivität: Human
Wirt: Synthetic
BP, WB
-
- Target Alle TSG101 Produkte
- TSG101 (Tumor Susceptibility Gene 101 (TSG101))
- Protein Region
- Middle Region
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Sequenz
- TGPPNTSYMP GMPGGISPYP SGYPPNPSGY PGCPYPPGGP YPATTSSQYP
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-TS101 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- TSG101 (Tumor Susceptibility Gene 101 (TSG101))
- Hintergrund
-
The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.
Alias Symbols: TSG101,
Protein Size: 285 - Gen-ID
- 7251
-
Sie sind hier:
